Host |
Mouse |
Klon |
ZM21 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast tissue. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human CNN1 protein |
Lokalisation |
Cytoplasm |
Calponin-1
|
Zeta Corporation |
ZM21 |
7 ml |
Ready-to-use |
CE/IVD |
Z2341MP |
-
|
Host |
Mouse |
Klon |
ZM21 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast tissue. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human CNN1 protein |
Lokalisation |
Cytoplasm |
Calponin-1
|
Zeta Corporation |
ZM21 |
0.5 ml |
Concentrate |
CE/IVD |
Z2341MS |
-
|
Host |
Mouse |
Klon |
ZM21 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast tissue. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human CNN1 protein |
Lokalisation |
Cytoplasm |
Calponin-1
|
Zeta Corporation |
ZM21 |
0.1 ml |
Concentrate |
CE/IVD |
Z2341MT |
-
|
Host |
Rabbit |
Klon |
ZR297 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length CNN1 protein |
Lokalisation |
Cytoplasm |
Calponin-1
|
Zeta Corporation |
ZR297 |
1 ml |
Concentrate |
CE/IVD |
Z2612RL |
-
|
Host |
Rabbit |
Klon |
ZR297 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast tissue |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length CNN1 protein |
Lokalisation |
Cytoplasm |
Calponin-1
|
Zeta Corporation |
ZR297 |
7 ml |
Ready-to-use |
CE/IVD |
Z2612RP |
-
|
Host |
Rabbit |
Klon |
ZR297 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length CNN1 protein |
Lokalisation |
Cytoplasm |
Calponin-1
|
Zeta Corporation |
ZR297 |
0.5 ml |
Concentrate |
CE/IVD |
Z2612RS |
-
|
Host |
Rabbit |
Klon |
ZR297 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length CNN1 protein |
Lokalisation |
Cytoplasm |
Calponin-1
|
Zeta Corporation |
ZR297 |
0.1 ml |
Concentrate |
CE/IVD |
Z2612RT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM85 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Calretinin (Calbindin 2) protein fragment (around aa23-242) |
Lokalisation |
Cytoplasm and Nucleus |
Calretinin
|
Zeta Corporation |
ZM85 |
1 ml |
Concentrate |
CE/IVD |
Z2392ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM85 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Calretinin (Calbindin 2) protein fragment (around aa23-242) |
Lokalisation |
Cytoplasm and Nucleus |
Calretinin
|
Zeta Corporation |
ZM85 |
7 ml |
Ready-to-use |
CE/IVD |
Z2392MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM85 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Calretinin (Calbindin 2) protein fragment (around aa23-242) |
Lokalisation |
Cytoplasm and Nucleus |
Calretinin
|
Zeta Corporation |
ZM85 |
0.5 ml |
Concentrate |
CE/IVD |
Z2392MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM85 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Calretinin (Calbindin 2) protein fragment (around aa23-242) |
Lokalisation |
Cytoplasm and Nucleus |
Calretinin
|
Zeta Corporation |
ZM85 |
0.1 ml |
Concentrate |
CE/IVD |
Z2392MT |
-
|
Host |
Mouse |
Klon |
231/439 |
Format |
Purified |
Methode |
EL |
Isotyp |
Mouse IgG |
Verdünnung |
Native Candida albicans |
Candida albicans
|
Zytomed Systems GmbH |
231/439 |
200 µg |
Purified |
RUO |
603-0059 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
F, EL, IF |
Isotyp |
Rabbit IgG |
Candida albicans
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
603-0061 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Biotin |
Methode |
F, IF, EL, WB |
Isotyp |
Rabbit IgG |
Verdünnung |
Native Candida albicans |
Candida albicans (Type A) - Biotin
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Biotin |
RUO |
603-0063 |
-
|
Host |
Mouse |
Klon |
CPVI-2AI |
Format |
Purified |
Methode |
EL, P |
Isotyp |
Mouse IgG2a |
Canine/Feline Parvovirus (CPV)
|
Zytomed Systems GmbH |
CPVI-2AI |
250 µg |
Purified |
RUO |
603-0071 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from the second quarter of human Caspase 1 protein. |
Lokalisation |
Cytoplasm, nucleus |
Caspase-1
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-3914 |
-
|
Host |
Mouse |
Klon |
3CSP03 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
3CSP03 |
1 ml |
Concentrate |
RUO |
MOB309 |
-
|
Host |
Mouse |
Klon |
3CSP03 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
3CSP03 |
0.1 ml |
Concentrate |
RUO |
MOB309-01 |
-
|
Host |
Mouse |
Klon |
3CSP03 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
3CSP03 |
0.5 ml |
Concentrate |
RUO |
MOB309-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
(Nuclear), Cytoplasmic |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
RUO |
RP096 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
(Nuclear), Cytoplasmic |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
RUO |
RP096-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
(Nuclear), Cytoplasmic |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RP096-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Caspase-3, cleaved (CPP32)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK009-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm, Cell Membrane |
Catenin (beta)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP080 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm, Cell Membrane |
Catenin (beta)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP080-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm, Cell Membrane |
Catenin (beta)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP080-05 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM13 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Fibromatosis or transitional cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human beta-catenin (CTNNB1) protein |
Lokalisation |
Membrane, Cytoplasm or Nucleus |
Catenin (beta)
|
Zeta Corporation |
ZM13 |
1 ml |
Concentrate |
CE/IVD |
Z2355ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM13 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Fibromatosis or transitional cell carcinoma. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human beta-catenin (CTNNB1) protein |
Lokalisation |
Membrane, Cytoplasm or Nucleus |
Catenin (beta)
|
Zeta Corporation |
ZM13 |
7 ml |
Ready-to-use |
CE/IVD |
Z2355MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM13 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Fibromatosis or transitional cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human beta-catenin (CTNNB1) protein |
Lokalisation |
Membrane, Cytoplasm or Nucleus |
Catenin (beta)
|
Zeta Corporation |
ZM13 |
0.5 ml |
Concentrate |
CE/IVD |
Z2355MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM13 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Fibromatosis or transitional cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human beta-catenin (CTNNB1) protein |
Lokalisation |
Membrane, Cytoplasm or Nucleus |
Catenin (beta)
|
Zeta Corporation |
ZM13 |
0.1 ml |
Concentrate |
CE/IVD |
Z2355MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Cathepsin D
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR004 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:75 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Cathepsin D
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP004 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:75 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Cathepsin D
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP004-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:75 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Cathepsin D
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP004-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
WB, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Human lymph node tissue |
Verdünnung |
20 µg/mL (P) |
Isotyp |
Rabbit IgG |
Verdünnung |
Peptide corresponding to amino acids 6 to 20 of human CCR5 |
CCR5 (HIV and Chemokine receptor)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Purified |
RUO |
603-0129 |
-
|
Host |
Mouse |
Klon |
O10 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cell membrane, cytoplasm |
CD1a
|
Biocare Medical |
O10 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3158A |
-
|
Host |
Mouse |
Klon |
O10 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cell membrane, cytoplasm |
CD1a
|
Biocare Medical |
O10 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3158B |
-
|
Host |
Mouse |
Klon |
O10 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Lokalisation |
Cell membrane, cytoplasm |
CD1a
|
Biocare Medical |
O10 |
6 ml |
Ready-to-use |
CE/IVD |
API3158AA |
-
|
Host |
Mouse |
Klon |
O10 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm, Cell Membrane |
CD1a
|
Diagnostic Biosystems |
O10 |
1 ml |
Concentrate |
CE/IVD |
MOB363 |
-
|
Host |
Mouse |
Klon |
O10 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm, Cell Membrane |
CD1a
|
Diagnostic Biosystems |
O10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB363-01 |
-
|
Host |
Mouse |
Klon |
O10 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm, Cell Membrane |
CD1a
|
Diagnostic Biosystems |
O10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB363-05 |
-
|
Host |
Mouse |
Klon |
O10 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm, Cell Membrane |
CD1a
|
Diagnostic Biosystems |
O10 |
6 ml |
Ready-to-use |
CE/IVD |
PDM173 |
-
|
Host |
Mouse |
Klon |
O10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin or Langerhans cell histiocytosis X. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
CD1a |
Lokalisation |
Cell membrane and Cytoplasm |
CD1a
|
Zeta Corporation |
O10 |
1.0 ml |
Concentrate |
CE/IVD |
Z2096ML |
-
|
Host |
Mouse |
Klon |
O10 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin or Langerhans cell histiocytosis X. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
CD1a |
Lokalisation |
Cell membrane and Cytoplasm |
CD1a
|
Zeta Corporation |
O10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2096MP |
-
|
Host |
Mouse |
Klon |
O10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin or Langerhans cell histiocytosis X. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
CD1a |
Lokalisation |
Cell membrane and Cytoplasm |
CD1a
|
Zeta Corporation |
O10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2096MS |
-
|
Host |
Mouse |
Klon |
O10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin or Langerhans cell histiocytosis X. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
CD1a |
Lokalisation |
Cell membrane and Cytoplasm |
CD1a
|
Zeta Corporation |
O10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2096MT |
-
|
Host |
Rabbit |
Klon |
SP304 |
Format |
Concentrate |
Methode |
IHC-P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant human CD2 protein |
Lokalisation |
Cell membrane |
CD2
|
Zytomed Systems GmbH |
SP304 |
0.1 ml |
Concentrate |
RUO |
503-6040 |
-
|
Host |
Mouse |
Klon |
UCHT1 |
Format |
Purified |
Methode |
F, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human infant thymocytes and lymphocytes from a patient with Sezary Syndrome |
CD3
|
Zytomed Systems GmbH |
UCHT1 |
200 µg |
Purified |
RUO |
603-0189 |
-
|
Host |
Rat |
Klon |
KT3 |
Format |
Purified |
Methode |
F, FL |
Isotyp |
Rat IgG2a |
CD3
|
Zytomed Systems GmbH |
KT3 |
100 µg |
Purified |
RUO |
603-0191 |
-
|
Host |
Mouse |
Klon |
1F4 |
Format |
Purified |
Methode |
F, P, IP, FL |
Vorbehandlung |
Citrate |
Verdünnung |
1:10 (P) |
Isotyp |
Mouse IgM |
Verdünnung |
F344 rat T cells stimulated with PMA (TPA) and calcium ionophore |
CD3
|
Zytomed Systems GmbH |
1F4 |
100 µg |
Purified |
RUO |
603-0193 |
-
|